Epidemiology of vasopressin use for adults with septic shock

Emily A. Vail, Hayley B. Gershengorn, May Hua, Allan J. Walkey, Hannah Wunsch

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Rationale: Vasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock. Objectives: We conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use. Methods: This was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation. Measurements and Main Results: Among 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2%) received vasopressin.Atotal of 6.1% of patients receiving vasopressin received vasopressin alone, and 93.9% received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6% over the study period, representing an average annual relative increase of 8% (P,0.001). The median hospital rate of vasopressin use for septic shock was 11.7% (range, 0-69.7%). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age.85 yr compared with the reference group of age,50 yr; 95% confidence interval, 0.69-0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95% confidence interval, 3.20-3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37). Conclusions: Approximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.

Original languageEnglish (US)
Pages (from-to)1760-1767
Number of pages8
JournalAnnals of the American Thoracic Society
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Septic Shock
Vasopressins
Epidemiology
Odds Ratio
Confidence Intervals
Hypotension
Cohort Studies
Retrospective Studies
Age Groups
Logistic Models
Demography

Keywords

  • Practice variation
  • Septic shock
  • Vasoconstrictor agents

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Cite this

Vail, E. A., Gershengorn, H. B., Hua, M., Walkey, A. J., & Wunsch, H. (2016). Epidemiology of vasopressin use for adults with septic shock. Annals of the American Thoracic Society, 13(10), 1760-1767. https://doi.org/10.1513/AnnalsATS.201604-259OC

Epidemiology of vasopressin use for adults with septic shock. / Vail, Emily A.; Gershengorn, Hayley B.; Hua, May; Walkey, Allan J.; Wunsch, Hannah.

In: Annals of the American Thoracic Society, Vol. 13, No. 10, 01.10.2016, p. 1760-1767.

Research output: Contribution to journalArticle

Vail, EA, Gershengorn, HB, Hua, M, Walkey, AJ & Wunsch, H 2016, 'Epidemiology of vasopressin use for adults with septic shock', Annals of the American Thoracic Society, vol. 13, no. 10, pp. 1760-1767. https://doi.org/10.1513/AnnalsATS.201604-259OC
Vail, Emily A. ; Gershengorn, Hayley B. ; Hua, May ; Walkey, Allan J. ; Wunsch, Hannah. / Epidemiology of vasopressin use for adults with septic shock. In: Annals of the American Thoracic Society. 2016 ; Vol. 13, No. 10. pp. 1760-1767.
@article{aa5696fc5cfa4ca79992e572430a5a3a,
title = "Epidemiology of vasopressin use for adults with septic shock",
abstract = "Rationale: Vasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock. Objectives: We conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use. Methods: This was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation. Measurements and Main Results: Among 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2{\%}) received vasopressin.Atotal of 6.1{\%} of patients receiving vasopressin received vasopressin alone, and 93.9{\%} received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6{\%} over the study period, representing an average annual relative increase of 8{\%} (P,0.001). The median hospital rate of vasopressin use for septic shock was 11.7{\%} (range, 0-69.7{\%}). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age.85 yr compared with the reference group of age,50 yr; 95{\%} confidence interval, 0.69-0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95{\%} confidence interval, 3.20-3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37). Conclusions: Approximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.",
keywords = "Practice variation, Septic shock, Vasoconstrictor agents",
author = "Vail, {Emily A.} and Gershengorn, {Hayley B.} and May Hua and Walkey, {Allan J.} and Hannah Wunsch",
year = "2016",
month = "10",
day = "1",
doi = "10.1513/AnnalsATS.201604-259OC",
language = "English (US)",
volume = "13",
pages = "1760--1767",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Epidemiology of vasopressin use for adults with septic shock

AU - Vail, Emily A.

AU - Gershengorn, Hayley B.

AU - Hua, May

AU - Walkey, Allan J.

AU - Wunsch, Hannah

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Rationale: Vasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock. Objectives: We conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use. Methods: This was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation. Measurements and Main Results: Among 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2%) received vasopressin.Atotal of 6.1% of patients receiving vasopressin received vasopressin alone, and 93.9% received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6% over the study period, representing an average annual relative increase of 8% (P,0.001). The median hospital rate of vasopressin use for septic shock was 11.7% (range, 0-69.7%). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age.85 yr compared with the reference group of age,50 yr; 95% confidence interval, 0.69-0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95% confidence interval, 3.20-3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37). Conclusions: Approximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.

AB - Rationale: Vasopressin may be used to treat vasodilatory hypotension in septic shock, but it is not recommended by guidelines as a first- or second-line agent. Little is known about how often the drug is used currently in septic shock. Objectives: We conducted this study to describe patterns of vasopressin use in a large cohort of U.S. adults with septic shock and to identify patient and hospital characteristics associated with vasopressin use. Methods: This was a retrospective cohort study of adults admitted to U.S. hospitals with septic shock in the Premier healthcare database (July 2008 to June 2013). We performed multilevel mixed-effects logistic regression with hospitals as a random effect to identify factors associated with use of vasopressin alone or in combination with other vasopressors on at least 1 day of hospital admission. We calculated quotients of Akaike Information Criteria (AIC) to determine relative contributions of patient and hospital characteristics to observed variation. Measurements and Main Results: Among 584,421 patients with septic shock in 532 hospitals, 100,923 (17.2%) received vasopressin.Atotal of 6.1% of patients receiving vasopressin received vasopressin alone, and 93.9% received vasopressin in combination with other vasopressors (up to five vasopressors in 15 different combinations). The mean monthly rate of vasopressin use increased from 14.5 to 19.6% over the study period, representing an average annual relative increase of 8% (P,0.001). The median hospital rate of vasopressin use for septic shock was 11.7% (range, 0-69.7%). Patient demographic and clinical characteristics, including patient age (adjusted odds ratio, 0.71 for age.85 yr compared with the reference group of age,50 yr; 95% confidence interval, 0.69-0.74) and acute respiratory dysfunction (adjusted odds ratio, 3.25; 95% confidence interval, 3.20-3.31), were responsible for the majority of observed variation in vasopressin use (quotient of AICs, 0.56). However, hospital of admission also contributed substantially to observed variation (quotient of AICs, 0.37). Conclusions: Approximately one-fifth of patients with septic shock received vasopressin, but rarely as a single vasopressor. The use of vasopressin has increased over time. The likelihood of receiving vasopressin was strongly associated with the specific hospital to which each patient was admitted.

KW - Practice variation

KW - Septic shock

KW - Vasoconstrictor agents

UR - http://www.scopus.com/inward/record.url?scp=84992665702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992665702&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201604-259OC

DO - 10.1513/AnnalsATS.201604-259OC

M3 - Article

VL - 13

SP - 1760

EP - 1767

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 10

ER -